000			01362nam a2200217Ia 4500
003			MX-MdCICY
005			20250625153850.0
040			_cCICY
090			_aB-12290
245	1	0	_aWhat made sesquiterpene lactones reach cancer clinical trials?
490	0		_vDrug Discovery Today, 15(15-16), p.668-678, 2010
520	3		_aSesquiterpene lactones (SLs)are plant-derived compounds often used in traditional medicine against inflammation and cancer. This review focuses on the chemical and biological properties of SLs that lead to enhanced anticancer and anti-inflammatory effects. The chemical properties comprise alkylating center reactivity, lipophilicity, and molecular geometry and electronic features. SLs in clinical trials are artemisinin, thapsigargin and parthenolide and many of their synthetic derivatives. These drugs are selective toward tumor and cancer stem cells by targeting specific signaling pathways, which make them head compounds in cancer clinical trials.
700	1	2	_aGhantous, A.
700	1	2	_aGali-Muhtasib, H.
700	1	2	_aVuorela, H.
700	1	2	_aSaliba, N.A.
700	1	2	_aDarwiche, N.
856	4	0	_uhttps://drive.google.com/file/d/1cW59fERkdG14w3Ko3h_ioXdQDpAKty_3/view?usp=drivesdk _zPara ver el documento ingresa a Google con tu cuenta: @cicy.edu.mx
942			_2Loc _cREF1
008			250602s9999 xx |||||s2 |||| ||und|d
999			_c46500 _d46500